TriangleCombination 5-azacytidine and… (NCT05317000)
Combination 5-azacytidine and nivolumab trial for Squamous Cell Carcinoma of Head and Neck (NCT05317000). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people older than eighteen with operable, HPV-associated oropharyngeal cancer, staged T1–T3, N0–N2, M0. Prior treatment of that tumor excludes entry; research biopsies are required.
The idea: random assignment compares nivolumab with nivolumab plus five days of azacytidine before surgery. Nivolumab blocks the PD1 immune brake. Azacytidine alters DNA methylation; researchers test whether it increases immune sensitivity. Surgical tissue measures response. The azacytidine-only arm is closed.
This phase 2 study plans 50 patients. Barbara Burtness leads at Yale, New Haven, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.